GC Biopharma Enhances Ig Therapy Through Education and Patient Insight at 2025 IgNS Meeting

GC Biopharma USA, Inc., a prominent player in the field of plasma-derived products, has taken significant strides in enhancing the standards of immunoglobulin therapy. This commitment was showcased during the recent 2025 Immunoglobulin National Society (IgNS) Annual Meeting, where the company actively supported data analysis and the publication of the 2025 IgNS Patient 360 Longitudinal Survey results. This initiative reflects GC Biopharma's dedication to elevating safety, education, and patient-centric approaches in immunoglobulin therapy.

The 2025 Patient 360 Longitudinal Survey is an ongoing research project designed to evaluate vital aspects such as patient outcomes, clinician competency, infusion safety, and identifying gaps in education concerning intravenous and subcutaneous immunoglobulin therapy. During the IgNS meeting, two posters presented by IgNS summarized new findings from this vital initiative. These findings emphasized the importance of structured education, adherence to best practices, and consistent monitoring, which can significantly improve infusion safety and bolster patient confidence when receiving intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) treatments.

Moreover, the findings demonstrated how strict adherence to national standards and evidence-based practices in nursing and pharmacy can enhance the quality of infusion therapy, positively impacting the overall patient experience.

In addition to data support, GC Biopharma also hosted a breakfast symposium titled, "From Patient Voices to Clinical Choices: Bridging Perspectives in Primary Immunodeficiency." The symposium garnered overwhelmingly positive feedback from attendees, with an impressive 96% of participants agreeing the session effectively met its educational objectives. Attendees praised the session for including perspectives from both patients and clinicians, describing it as "very informative," "easily understandable," and "a fantastic presentation."

Dr. Stacey Ness, a key figure in GC Biopharma’s Medical Affairs, expressed the company's commitment to integrate patient voices with clinical insights to better understand and tackle the challenges in immunoglobulin treatment. She explained, “By supporting research like the IgNS Patient 360 data analysis and programs where patient experiences inform clinical decision-making, we can advance quality care and foster collaboration.”

With a robust legacy of over 50 years in plasma protein manufacturing, GC Biopharma remains committed to elevating the standards within the IVIG therapy landscape. The company's product, ALYGLO®, an immune globulin for intravenous infusion, further underscores its dedication to safety and quality. The ALYGLO manufacturing process boasts stringent protocols to minimize the risk of virus transmission, utilizing practices like solvent/detergent treatment and nanofiltration. ALYGLO, which is glycine-stabilized and consists of 10% immunoglobulin G, is indicated for the treatment of primary humoral immunodeficiency in adults.

By advancing educational initiatives and supporting thorough research efforts, GC Biopharma is not only enhancing the patient experience but also establishing a formidable foundation for future innovations in immunoglobulin therapy. As they look to the future, GC Biopharma's mission remains clear: to radically improve patient outcomes through education, safety, and patient-centered care in the realm of immunotherapy.

Conclusion

GC Biopharma’s initiatives at the 2025 IgNS Annual Meeting exemplify a vital intersection of education and patient care in the evolving field of immunoglobulin therapy. The company stands poised to further its commitment to enhancing treatment standards and patient experiences, ensuring that advances in therapy align closely with the voices of patients and healthcare providers alike.